Stop using now Drug recall · FDA · Published December 18, 2025

Imprimis Tri-Moxi+ Intraocular Injection Recall: Glass Particles Risk

Imprimis recalls Tri-Moxi+ eye injections due to glass particles. Stop using if you have the specific lot numbers listed. Contact for details.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-0251-2026Drug Imprimis ›

Stop using this now

Presence of particulate matter - Glass like particles.

Take action

Contact the company

Recalling firmImprimis NJOF, LLC1705 Route 46 Ste 6B · Ledgewood, NJ 07852-9720

✎ GovInfoNow plain-language explainer

Imprimis is recalling Tri-Moxi+ eye injections because they may contain glass particles. This could cause serious eye injury if injected. Affected products have specific lot numbers and expiration dates. Read more at govinfonow.com/recall/31608-imprimis-tri-moxi-intraocular-injection-recall-glass-particles-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/31608-imprimis-tri-moxi-intraocular-injection-recall-glass-particles-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0251-2026

Cite this page

“Imprimis Tri-Moxi+ Intraocular Injection Recall: Glass Particles Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31608-imprimis-tri-moxi-intraocular-injection-recall-glass-particles-risk. Based on FDA recall #D-0251-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0251-2026%22&limit=1).

The FDA announced on Dec. 18, 2025, that Imprimis NJOF, LLC is recalling Tri-Moxi+ intraocular injections due to the presence of glass-like particulate matter. Owners should stop using the product immediately.

How to tell if you have it

Brand: Imprimis
Product: Tri-Moxi+ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection
NDC: 71384-746-06
Lot codes: 25JAN033A, 25JAN033B
Expiration date: 02/12/2026
Quantity: 314 boxes of 6,280 pre-filled syringes
Distribution: U.S. Nationwide

The hazard

The recall addresses the presence of particulate matter described as glass-like particles in the single-use intraocular injections.

Context

GovInfoNow's records show Imprimis NJOF, LLC has had 13 other recalls since Dec. 17, 2020. Recent similar recalls include a subpotent drug risk for Klarity-C Drops on Oct. 20, 2025, and an epinephrine vial recall on July 9, 2025. Other recent recalls of similar products include the Fresenius Kabi Tyenne Injection (Aug. 10, 2026), ImprimisRx Povidone Iodine Ophthalmic Solution (Aug. 24, 2026), and Sun Pharmaceutical DOXOrubin Liposome Injection (May 12, 2026).

How to tell if you have this one

Check the lot number on the product label. The recalled items have lot numbers 25JAN033A or 25JAN033B and expire by February 12, 2026.

Brand
Imprimis
Category
Drug

FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

Classification
Class II
Status
Ongoing
Distribution
U.S Nationwide

Recall number	Product, codes & lots	Quantity
D-0249-2026	Dexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, Rx only, Imprimis NJOF, LLC, Ledgewood, NJ 07852, NDC 71384-512-0.1; Lot: 25MAY051, Expires: 06/26/2026; 25AUG003, Expires:08/07/2026	778 boxes of 15,540 pre-filled syringes
D-0250-2026	Dexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852, NDC 71384-513-01.; Lot: 25APR001A, 25APR001B, Expires: 04/03/2026.	596 boxes of 11,920 pre-filled syringes
D-0251-2026	Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.; Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.	314 boxes of 6,280 pre-filled syringes

Based on the official FDA remedy

What to do — step by step

Stop Using Now
Immediately stop using the recalled Tri-Moxi+ eye injections if you have the specific lot numbers listed.

Where it went and when

Where it was distributed

Distributed nationwide.

FDA distribution: “U.S Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 27 days after the firm started it.

Dec 18, 2025Firm started the recall
Jan 2, 2026FDA classified it Class II
Jan 14, 2026Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Link to this recall

<a href="https://govinfonow.com/recall/31608-imprimis-tri-moxi-intraocular-injection-recall-glass-particles-risk">Imprimis Tri-Moxi+ Intraocular Injection Recall: Glass Particles Risk (GovInfoNow)</a>

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

Official source: FDA Recall #D-0251-2026 (December 18, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0251-2026 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.